Kathryn S. Kolibaba

5.2k total citations · 2 hit papers
93 papers, 3.5k citations indexed

About

Kathryn S. Kolibaba is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Kathryn S. Kolibaba has authored 93 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Genetics, 58 papers in Pathology and Forensic Medicine and 32 papers in Oncology. Recurrent topics in Kathryn S. Kolibaba's work include Chronic Lymphocytic Leukemia Research (63 papers), Lymphoma Diagnosis and Treatment (58 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Kathryn S. Kolibaba is often cited by papers focused on Chronic Lymphocytic Leukemia Research (63 papers), Lymphoma Diagnosis and Treatment (58 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Kathryn S. Kolibaba collaborates with scholars based in United States, Canada and Australia. Kathryn S. Kolibaba's co-authors include Brian Druker, Sayuri Ohno-Jones, Jeff P. Sharman, Thomas E. Boyd, Ranjana H. Advani, Nathan Fowler, Joseph J. Buggy, Barbara Grant, Ahmed Hamdy and Sonali M. Smith and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Kathryn S. Kolibaba

91 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2012 848 citations Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology profile →
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathryn S. Kolibaba United States	22	2.0k	2.0k	1.4k	1.0k	710	93	3.5k
Andrzej Hellmann Poland	23	1.3k 0.6×	1.8k 0.9×	589 0.4×	1.5k 1.5×	548 0.8×	58	3.1k
John C. Byrd United States	19	1.0k 0.5×	1.4k 0.7×	720 0.5×	1.7k 1.6×	1.5k 2.1×	81	3.7k
Francisco J. Hernandez‐Ilizaliturri United States	30	2.0k 1.0×	1.4k 0.7×	1.6k 1.1×	593 0.6×	1.1k 1.5×	192	3.7k
Jeffrey Matous United States	29	2.3k 1.1×	1.6k 0.8×	1.8k 1.3×	1.2k 1.2×	1.0k 1.4×	128	4.2k
Paul M. Barr United States	32	2.6k 1.3×	2.5k 1.3×	1.2k 0.8×	848 0.8×	642 0.9×	188	3.9k
Ellen Schlette United States	28	1.3k 0.7×	1.3k 0.7×	700 0.5×	412 0.4×	701 1.0×	69	2.3k
Brian J. Lannutti United States	29	1.7k 0.8×	2.6k 1.3×	831 0.6×	991 1.0×	1.8k 2.6×	75	4.0k
Leslie A. Andritsos United States	30	1.5k 0.7×	2.1k 1.0×	1.0k 0.7×	866 0.9×	967 1.4×	161	3.5k
Enrico Tiacci Italy	27	1.1k 0.5×	1.1k 0.5×	703 0.5×	811 0.8×	1.1k 1.6×	77	2.8k
Markus Warmuth United States	27	412 0.2×	885 0.5×	930 0.7×	1.2k 1.2×	1.7k 2.4×	48	3.1k

Countries citing papers authored by Kathryn S. Kolibaba

Since Specialization

Citations

This map shows the geographic impact of Kathryn S. Kolibaba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn S. Kolibaba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn S. Kolibaba more than expected).

Fields of papers citing papers by Kathryn S. Kolibaba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn S. Kolibaba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn S. Kolibaba. The network helps show where Kathryn S. Kolibaba may publish in the future.

Co-authorship network of co-authors of Kathryn S. Kolibaba

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn S. Kolibaba. A scholar is included among the top collaborators of Kathryn S. Kolibaba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn S. Kolibaba. Kathryn S. Kolibaba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hawkes, Eliza A., Katharine L. Lewis, Nicole Wong Doo, et al.. (2023). First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma. Hematological Oncology. 41(S2). 579–580. 1 indexed citations

Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058. 18 indexed citations

Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations

Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2021). Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study. Blood. 138(Supplement 1). 3725–3725. 1 indexed citations

Zeidner, Joshua F., Daniel J. Lee, Mark G. Frattini, et al.. (2020). Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. Clinical Cancer Research. 27(1). 60–69. 18 indexed citations

Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2020). MAGNIFY phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology. 38(15_suppl). 8046–8046. 8 indexed citations

Tilly, Hervé, Franck Morschhauser, Nancy L. Bartlett, et al.. (2019). Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. The Lancet Oncology. 20(7). 998–1010. 93 indexed citations

Phillips, Tycel, Paul M. Barr, Steven I. Park, et al.. (2018). A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs. 37(2). 297–306. 57 indexed citations

Kahl, Brad S., John M. Burke, Richard van der Jagt, et al.. (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood. 130. 484–484. 10 indexed citations

10.

Flinn, Ian W., Richard van der Jagt, Julie Chang, et al.. (2017). FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY. Hematological Oncology. 35(S2). 140–141. 9 indexed citations

11.

Sharman, Jeff P., Charles M. Farber, Daruka Mahadevan, et al.. (2016). Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology. 176(3). 412–420. 44 indexed citations

12.

Yasenchak, Christopher A., Ahmad Halwani, Ranjana H. Advani, et al.. (2015). Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. Blood. 126(23). 814–814. 7 indexed citations

13.

Leonard, John P., Kathryn S. Kolibaba, James A. Reeves, et al.. (2015). Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918). Blood. 126(23). 811–811. 32 indexed citations

14.

Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952. 419 indexed citations breakdown →

15.

Sharman, Jeff P., Charles M. Farber, Daruka Mahadevan, et al.. (2014). Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial. Blood. 124(21). 4679–4679. 13 indexed citations

16.

Advani, Ranjana H., Joseph J. Buggy, Jeff P. Sharman, et al.. (2012). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology. 31(1). 88–94. 848 indexed citations breakdown →

17.

Ohno-Jones, Sayuri, et al.. (2000). Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells. Blood. 96(9). 3195–3199. 209 indexed citations

18.

Kolibaba, Kathryn S., et al.. (1999). CRKL Binding to BCR-ABL and BCR-ABL Transformation. Leukemia & lymphoma. 33(1-2). 119–126. 10 indexed citations

19.

Kolibaba, Kathryn S., et al.. (1997). Direct Binding of CRKL to BCR-ABL Is Not Required for BCR-ABL Transformation. Blood. 89(1). 297–306. 2 indexed citations

20.

Bhat, Arun, et al.. (1997). Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells. Journal of Biological Chemistry. 272(26). 16170–16175. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact